Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 19, 2012

Primary Completion Date

June 7, 2016

Study Completion Date

March 1, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

carfilzomib

45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.

DRUG

Dexamethasone

20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.

DRUG

Clarithromycin

500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

DRUG

Lenalidomide

25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

DRUG

Dexamethasone

40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

DRUG

Lenalidomide

10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Onyx Therapeutics, Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT01559935 - Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | Biotech Hunter | Biotech Hunter